Autolus Therapeutics plc Operating Lease Cost
Autolus Therapeutics plc (AUTL) reported Operating Lease Cost of $2.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-11
- Autolus Therapeutics plc operating lease, cost for the quarter ending 2026-06-30 was $2.48M, a 16.20% increase year-over-year.
- Autolus Therapeutics plc operating lease, cost for the quarter ending 2026-03-31 was $2.61M, a 20.17% increase year-over-year.
- Autolus Therapeutics plc operating lease, cost for the quarter ending 2025-09-30 was $2.15M, a 0.05% decline year-over-year.
- Autolus Therapeutics plc operating lease, cost for the quarter ending 2025-06-30 was $2.14M, a 2.35% increase year-over-year.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month |
|---|---|---|---|
| 2026-06-30 | $2.48M 10-Q · filed 2026-08-11 | $5.09M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $2.61M 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | $2.15M 10-Q · filed 2025-11-12 | $4.29M derived: sum of 2 quarters · filed 2026-08-11 | $6.46M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.14M 10-Q · filed 2026-08-11 | $4.31M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $2.17M 10-Q · filed 2026-05-14 | ||
| 2024-09-30 | $2.15M 10-Q · filed 2025-11-12 | $4.24M derived: sum of 2 quarters · filed 2025-11-12 | $6.34M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $2.09M 10-Q · filed 2025-08-12 | $4.18M 10-Q · filed 2025-08-12 | |
| 2024-03-31 | $2.10M 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $2.06M 10-Q · filed 2024-11-12 | $3.87M derived: sum of 2 quarters · filed 2024-11-12 | $5.24M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $1.81M 10-Q · filed 2024-08-08 | $3.17M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $1.37M 10-Q · filed 2024-05-17 | ||
| 2022-09-30 | $1.10M 10-Q · filed 2023-11-09 | $3.54M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |